Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170590 | 0.88 | TSHR (0.48) | TACR1TSHRMEN1KMT2ACYP2C9 | |
| SCHEMBL28654159 | 0.82 | TACR1 (0.45) | TACR1TSHRMEN1KMT2ACYP2C9 | |
| SCHEMBL100117 | 0.82 | TACR1 (0.45) | TACR1TSHRMEN1KMT2ACYP2C9 | |
| SCHEMBL1668138 | 0.81 | L3MBTL1 (0.41) | TSHRL3MBTL1GAAPOLBMEN1 | |
| SCHEMBL17611895 | 0.81 | TACR1 (0.44) | TACR1TSHRL3MBTL1GAAPOLB | |
| SCHEMBL12346120 | 0.80 | L3MBTL1 (0.40) | TSHRL3MBTL1GAAPOLBMEN1 | |
| SCHEMBL416619 | 0.78 | TACR1 (0.42) | TACR1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL17320197 | 0.78 | TACR1 (0.42) | TACR1TSHRL3MBTL1GAAPOLB | |
| SCHEMBL31721328 | 0.78 | L3MBTL1 (0.40) | TSHRL3MBTL1GAAPOLBMEN1 | |
| SCHEMBL19415682 | 0.78 | TSHR (0.44) | TACR1TSHRMEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230799-A2 | CYCLOALKYL- AND PIPERIDINYL-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-2565184-B1 | THERAPEUTIC AGENT AND PREVENTATIVE AGENT FOR ALZHEIMER'S DISEASE | TORAY INDUSTRIES (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2565184-B1 | THERAPEUTIC AGENT AND PREVENTATIVE AGENT FOR ALZHEIMER'S DISEASE | TORAY INDUSTRIES (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2554541-B1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | TORAY INDUSTRIES (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8957094-B2 | Therapeutic agent or prophylactic agent for fibromyalgia | TORAY INDUSTRIES, INC. (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957094-B2 | Therapeutic agent or prophylactic agent for fibromyalgia | TORAY INDUSTRIES, INC. (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957094-B2 | Therapeutic agent or prophylactic agent for fibromyalgia | TORAY INDUSTRIES, INC. (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2341047-B1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2562160-B1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR URINE COLLECTION DISORDER | TORAY INDUSTRIES (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-8642625-B2 | Therapeutic agent or preventive agent for urine collection disorder | TORAY INDUSTRIES, INC. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-8247569-B2 | Cyclohexane derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247569-B2 | Cyclohexane derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2012-08-21 | — | — | US | disclosed |
| WO-2011125836-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | 東レ株式会社 (JP) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011125838-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR URINE COLLECTION DISORDER | 東レ株式会社 (JP) | 2011-10-13 | — | — | WO | disclosed |
| US-20110201650-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201650-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201650-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2341047-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341047-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010050577-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201650-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, TRPV1, OPRL1 | TACR1 116/4885TSHR 4441/4885L3MBTL1 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.